Total Payments
$21,096
2024 Payments
$124.58
Companies
29
Transactions
179
Medicare Patients
1,003
Medicare Billing
$266,701
Payment Breakdown by Category
Other$11,340 (53.8%)
Consulting$5,475 (26.0%)
Food & Beverage$3,067 (14.5%)
Travel$1,135 (5.4%)
Education$78.95 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,340 | 15 | 53.8% |
| Consulting Fee | $5,475 | 3 | 26.0% |
| Food and Beverage | $3,067 | 149 | 14.5% |
| Travel and Lodging | $1,135 | 9 | 5.4% |
| Education | $78.95 | 3 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $18,557 | 45 | $0 (2019) |
| Amgen Inc. | $421.48 | 23 | $0 (2019) |
| Genentech USA, Inc. | $282.83 | 31 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $240.00 | 6 | $0 (2017) |
| GlaxoSmithKline, LLC. | $226.52 | 8 | $0 (2020) |
| Aurinia Pharma U.S., Inc. | $213.29 | 2 | $0 (2022) |
| AbbVie, Inc. | $181.59 | 15 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $137.96 | 2 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $124.99 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $118.21 | 9 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $124.58 | 1 | AstraZeneca Pharmaceuticals LP ($124.58) |
| 2023 | $124.99 | 1 | Alexion Pharmaceuticals, Inc. ($124.99) |
| 2022 | $213.29 | 2 | Aurinia Pharma U.S., Inc. ($213.29) |
| 2021 | $13.32 | 1 | BOSTON SCIENTIFIC CORPORATION ($13.32) |
| 2020 | $107.87 | 1 | GlaxoSmithKline, LLC. ($107.87) |
| 2019 | $7,797 | 33 | Lilly USA, LLC ($7,565) |
| 2018 | $11,498 | 80 | Lilly USA, LLC ($10,722) |
| 2017 | $1,217 | 60 | Lilly USA, LLC ($270.33) |
All Payment Transactions
179 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/08/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $124.58 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 04/13/2023 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Rare Disease | ||||||
| 11/12/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $88.29 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 04/27/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 03/09/2021 | BOSTON SCIENTIFIC CORPORATION | GENERAL PAIN MANAGEMENT (Device) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: PAIN MANAGEMENT | ||||||
| 01/29/2020 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $107.87 | General |
| Category: IMMUNOLOGY | ||||||
| 08/23/2019 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $78.38 | General |
| Category: Immunology | ||||||
| 08/23/2019 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $11.76 | General |
| Category: Immunology | ||||||
| 08/23/2019 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $6.27 | General |
| Category: Immunology | ||||||
| 07/30/2019 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: IMMUNOLOGY | ||||||
| 07/18/2019 | Lilly USA, LLC | — | Education | In-kind items and services | $1.00 | General |
| 07/12/2019 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: IMMUNOLOGY | ||||||
| 06/18/2019 | Genentech, Inc. | Rituxan (Biological) | Education | In-kind items and services | $39.95 | General |
| Category: BioOncology/Immunology | ||||||
| 05/29/2019 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), BEXSERO, MENVEO | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: VACCINES | ||||||
| 05/08/2019 | Amgen Inc. | Prolia (Biological) | Food and Beverage | In-kind items and services | $12.75 | General |
| Category: Bone Health | ||||||
| 04/23/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug), INVOKANA | Food and Beverage | In-kind items and services | $10.92 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/17/2019 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/16/2019 | Lilly USA, LLC | OLUMIANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| Category: Immunology | ||||||
| 04/10/2019 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: Inflammation | ||||||
| 04/05/2019 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 04/05/2019 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: Immunology | ||||||
| 04/03/2019 | Lilly USA, LLC | OLUMIANT (Drug) | Travel and Lodging | Cash or cash equivalent | $84.56 | General |
| Category: Immunology | ||||||
| 03/29/2019 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $12.13 | General |
| 03/27/2019 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: Immunology | ||||||
| 03/21/2019 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 234 | 2,762 | $215,224 | $77,194 |
| 2022 | 9 | 270 | 3,144 | $236,360 | $83,412 |
| 2021 | 7 | 259 | 2,183 | $190,550 | $65,197 |
| 2020 | 8 | 240 | 1,357 | $130,925 | $40,899 |
Total Patients
1,003
Total Services
9,446
Medicare Billing
$266,701
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 25 | 2,340 | $99,840 | $43,504 | 43.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 99 | 227 | $68,404 | $23,206 | 33.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 16 | 37 | $15,795 | $4,061 | 25.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 38 | 43 | $9,050 | $3,198 | 35.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $7,375 | $2,407 | 32.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 26 | 41 | $2,075 | $473.07 | 22.8% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 11 | 55 | $12,685 | $345.39 | 2.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 26 | 2,640 | $104,400 | $44,912 | 43.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 92 | 228 | $74,100 | $23,102 | 31.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 19 | 54 | $20,015 | $6,214 | 31.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 40 | 55 | $12,650 | $3,866 | 30.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $8,400 | $2,622 | 31.2% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 16 | 17 | $2,285 | $1,159 | 50.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 29 | 53 | $2,655 | $644.88 | 24.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 15 | 16 | $1,260 | $521.16 | 41.4% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2022 | 13 | 61 | $10,595 | $370.35 | 3.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 21 | 1,740 | $74,100 | $28,650 | 38.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 88 | 195 | $56,830 | $20,530 | 36.1% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 24 | 43 | $15,340 | $5,420 | 35.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 37 | 37 | $15,060 | $4,997 | 33.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 52 | 62 | $12,720 | $4,601 | 36.2% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2021 | 15 | 75 | $14,875 | $623.96 | 4.2% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 22 | 31 | $1,625 | $375.30 | 23.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 13 | 960 | $36,900 | $15,191 | 41.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 79 | 172 | $44,720 | $14,163 | 31.7% |
About Dr. Linda Brecher, DO
Dr. Linda Brecher, DO is a Rheumatology healthcare provider based in Stratford, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346297215.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Linda Brecher, DO has received a total of $21,096 in payments from pharmaceutical and medical device companies, with $124.58 received in 2024. These payments were reported across 179 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($11,340).
As a Medicare-enrolled provider, Brecher has provided services to 1,003 Medicare beneficiaries, totaling 9,446 services with total Medicare billing of $266,701. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Stratford, NJ
- Active Since 05/27/2006
- Last Updated 03/07/2024
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1346297215
Products in Payments
- OLUMIANT (Drug) $7,060
- FORTEO (Drug) $285.22
- Enbrel (Biological) $263.06
- SYNVISC-ONE (Device) $240.00
- LUPKYNIS (Drug) $213.29
- BENLYSTA (Biological) $210.90
- Actemra (Biological) $181.90
- Humira (Biological) $181.59
- Prolia (Biological) $131.58
- STRENSIQ (Biological) $124.99
- SAPHNELO (Biological) $124.58
- TALTZ (Drug) $124.35
- Rituxan (Biological) $123.41
- COSENTYX (Biological) $101.83
- SIMPONI ARIA (Biological) $77.16
- Tymlos (Biological) $67.03
- Perjeta (Biological) $55.47
- Cimzia (Drug) $50.91
- ORENCIA (Biological) $40.55
- XELJANZ (Drug) $38.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.